South Korea Phentermine Hydrochloride Market Size, Share, Growth, and Industry Analysis, By Dosage Form (Tablets, Capsules, Orally Disintegrating Tablets (ODT), Extended-Release Formulations), By Strength (8 mg, 15 mg, 18.75 mg, 30 mg) and Forecast, 2026-2034

South Korea Phentermine Hydrochloride Market Trends

Digital weight-management channels and next-generation obesity therapies reshape prescribing patterns

South Korea's weight-management pharmaceutical ecosystem is moving toward digitally mediated consultations, specialized obesity clinics, and increasingly differentiated pharmacotherapy. Competitive pressure has intensified as injectable incretin therapies broaden physician and consumer options. In November 2025, approximately 914,000 units of Wegovy and Mounjaro were reportedly supplied nationally, with about 65.8% concentrated in Greater Seoul, illustrating the scale and geographic concentration of contemporary anti-obesity pharmacotherapy demand.

South Korea Phentermine Hydrochloride Market Drivers

Rising obesity burden sustains prescription weight-management requirements

Increasing obesity prevalence is the principal structural demand driver. KDCA data show adult obesity prevalence reaching 34.4% in 2024, versus 26.3% ten years earlier, representing a 30.8% relative increase. Regional prevalence reached 36.8% in Jeonnam and Jeju, while even the lowest reported jurisdiction, Sejong, recorded 29.1%.

South Korea Phentermine Hydrochloride Market Opportunities

Specialty clinics and digitally enabled care expand patient-access pathways

The combination of a 34.4% national adult obesity prevalence and regional rates reaching 36.8% creates opportunities for structured weight-management programs integrating physician consultation, pharmacy dispensing, nutrition, and monitoring.

Challanges in South Korea Phentermine Hydrochloride Market

Intensifying therapeutic competition changes the obesity-treatment mix

Established sympathomimetic medicines face competition from GLP-1 and dual-incretin therapies offering different efficacy, administration, and treatment-duration profiles. Approximately 65.8% of the reported 914,000 Wegovy and Mounjaro units supplied during November 2025 went to Greater Seoul, including 34.5% to Seoul, 26.0% to Gyeonggi, and 5.3% to Incheon.

South Korea Phentermine Hydrochloride Market Segmentation

The market is segmented by dosage form, strength, route of administration, distribution channel, application, end user, and sales type. In 2026, tablets command approximately 43.46% of dosage-form revenue, while 8 mg products represent approximately 35.67% of strength-based revenue.

By Dosage Form

Tablets constitute the largest dosage-form segment at USD 3.29 million in 2026, increasing to USD 5.85 million by 2034 at a 7.47% CAGR. Their 2026 contribution is approximately 43.46%, supported by established prescribing practices, convenient administration, and broad familiarity among pharmacies and patients.

Capsules are the fastest-growing dosage form at 7.91% CAGR, rising from USD 1.95 million in 2026 to USD 3.59 million by 2034. ODT products increase from USD 1.51 million to USD 2.66 million at 7.29% CAGR, while extended-release formulations advance from USD 0.82 million to USD 1.45 million at 7.47% CAGR.

By Strength

The 8 mg category leads with USD 2.70 million in 2026, representing approximately 35.67%, and is forecast to reach USD 4.77 million in 2034 at a 7.39% CAGR. The 15 mg category follows at USD 1.88 million in 2026 and USD 3.41 million in 2034.

The fastest-growing strength is 30 mg, registering 7.99% CAGR and increasing from USD 1.07 million to USD 1.98 million. The 37.5 mg segment expands at 7.54% CAGR, while 18.75 mg records 7.02% CAGR.

By Route of Administration

Oral products form the established route, supported by tablet and capsule formats representing a combined 69.22% of 2026 dosage-form revenue. Sublingual delivery remains a differentiated route where rapid administration and patient convenience can influence product selection.

Across the forecast period, oral administration remains structurally supported by the USD 3.29 million tablet and USD 1.95 million capsule categories in 2026. Sublingual-format expansion will depend on product availability, physician acceptance, regulatory approvals, and formulation innovation through 2034.

By Distribution Channel

Hospital pharmacies, retail pharmacies, online-enabled pharmacy pathways, and weight-loss clinics constitute the distribution framework. Retail and clinic-based channels benefit from the prescription nature of the therapy, while Korea's national obesity prevalence of 34.4% indicates a substantial potential treatment population.

Specialized weight-loss clinics and digitally initiated care pathways are positioned for faster patient-engagement expansion as obesity pharmacotherapy becomes increasingly mainstream. The underlying market rises from USD 7.57 million in 2026 to approximately USD 13.55 million by 2034, creating incremental dispensing opportunities across supervised channels.

By Application

Obesity and overweight accompanied by comorbidities constitute the principal application groups. The national obesity rate reached 34.4% in 2024, while high-prevalence jurisdictions recorded 36.8%, emphasizing the clinical burden underlying pharmacological intervention.

Patients requiring pharmacotherapy alongside diet and exercise represent a medically supervised addressable population. As the total market expands at 7.53% CAGR through 2034, application demand will remain influenced by BMI thresholds, comorbidity burden, physician assessment, treatment duration, and competing obesity therapies.

By End User

Hospitals, ambulatory facilities, specialty weight-loss clinics, and homecare/telehealth users form the principal end-user groups. Specialty obesity services benefit from the increasing treatment burden associated with the 34.4% adult obesity prevalence reported nationally.

Homecare and digitally supported users represent an evolving access model, although prescription oversight remains essential. Against a total 2026 value of USD 7.57 million, increasing integration between remote consultation, clinical monitoring, and pharmacy fulfillment is expected to broaden supervised access through 2034.

By Sales Type

Generic drugs occupy an important position because phentermine is an established active ingredient supplied by domestic pharmaceutical manufacturers, while branded products compete through physician familiarity, formulation differentiation, and distribution relationships. A Korean-listed 37.5 mg phentermine hydrochloride tablet is manufactured by Chong Kun Dang Pharmaceutical.

South Korea Phentermine Hydrochloride Market Outlook

South Korea displays significant geographic variation in underlying obesity-treatment requirements. KDCA reported 36.8% adult obesity prevalence in both Jeonnam and Jeju, versus 29.1% in Sejong and 34.4% nationally. These epidemiological differences indicate comparatively stronger potential clinical need in higher-prevalence provinces, although prescription revenue cannot be allocated regionally from the supplied market tables.

Greater Seoul nevertheless demonstrates exceptionally high adoption of newer pharmacological obesity treatments. Of approximately 914,000 Wegovy and Mounjaro units reportedly supplied nationwide in November 2025, 65.8% went to Greater Seoul; Seoul accounted for 34.5%, Gyeonggi 26.0%, and Incheon 5.3%.

Top players in South Korea Phentermine Hydrochloride Market

• Chong Kun Dang Pharmaceutical Corp.
• Daewoong Pharmaceutical Co., Ltd.
• Hanmi Pharmaceutical Co., Ltd.
• Yuhan Corporation
• Kwangdong Pharmaceutical Co., Ltd.
• Boryung Corporation
• DongKook Pharmaceutical Co., Ltd.
• Dong-A ST Co., Ltd.
• JW Pharmaceutical Corporation
• HK inno.N Corporation

Top Company

• Chong Kun Dang Pharmaceutical Corp.

company-specific phentermine revenue share is not publicly disclosed. The company has directly verifiable positioning in South Korea's phentermine category through a listed prescription 37.5 mg phentermine hydrochloride tablet. However, those corporate revenues cannot legitimately be converted into a phentermine-specific percentage. Competitive positioning therefore rests on pharmaceutical distribution capabilities, physician relationships, manufacturing infrastructure, and access to Korea's expanding weight-management ecosystem rather than an unsupported numerical company-share estimate.

Recent Developments in South Korea Phentermine Hydrochloride Market

• 2026: Korean obesity-treatment competition continued intensifying as injectable incretin medicines expanded their commercial presence, challenging established oral appetite suppressants across clinic-based treatment pathways.
• 2025: KDCA reported adult obesity prevalence of 34.4%, based on the 2024 Community Health Survey, compared with 26.3% ten years earlier.
• 2025: Regional obesity prevalence reached 36.8% in Jeonnam and Jeju while Sejong recorded 29.1%, revealing a 7.7-percentage-point geographic spread in underlying disease burden.
• 2025: Approximately 914,000 units of Wegovy and Mounjaro were reportedly supplied nationally in November, with about 65.8% distributed in Greater Seoul, illustrating rapid adoption of competing pharmacological weight-management approaches.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, historical assessment across 2022–2024, and forecasts through 2034. Mandatory supplied numerical tables were treated as the primary source for market valuation, dosage-form contribution, strength contribution, and CAGR calculations. Segment percentages were calculated directly from supplied 2026 totals; for example, tablets equal approximately 43.46% of USD 7.57 million and 8 mg products equal approximately 35.67%. External authoritative information was used only to contextualize epidemiology, regulation, product availability, competition, and regional conditions where the supplied tables contain no corresponding figures. No unsupported manufacturer-level percentage shares or regional phentermine revenue allocations were substituted for unavailable primary data.